Valuation Services
How to Value a Company with No Revenue: Methods That Actually Work
Lekha Editorial Team
CA-reviewed · Published
Valuing a company with no revenue requires more art than a revenue-multiple calculation and more structure than 'what seems fair.' The methods that work for pre-revenue companies rely on two things: comparable transactions and a risk-adjusted view of what the company would be worth if its key risks were resolved.
Why Standard Valuation Methods Fail
Revenue multiples: no revenue, no multiple. EV/EBITDA: negative EBITDA, meaningless multiple. P/E ratio: no earnings. These methods produce no usable output for pre-revenue companies.
DCF: theoretically applicable, but the output is hyper-sensitive to assumptions that are essentially speculative. A pre-revenue DCF that shows ₹15 crore valuation can be reconstructed to show ₹5 crore or ₹50 crore by adjusting growth assumptions within a plausible range. The DCF provides structure, not precision.
The honest answer: pre-revenue valuations are negotiated, not calculated. The methods below give frameworks for the negotiation — not objective numbers that are 'right' and must be accepted.
Risk Factor Scoring: The Structured Approach
The risk factor scoring method adjusts a baseline valuation (typically the median deal value for comparable stage/sector) up or down based on an assessment of 10–12 risk factors. Each factor is scored on a scale of -2 (much below average) to +2 (much above average), with 0 being average for the sector. The scores are converted to percentage adjustments.
Common risk factors for Indian startups: management team strength, size of opportunity, product/technology differentiation, competitive landscape, marketing and sales channels, customer relationships in hand, strategic partnerships, additional funding requirements beyond this round, and litigation/regulatory risk.
Example: baseline valuation ₹8 crore. Team is exceptional (+2, +25%). Market size is moderate (0, no adjustment). Product has unique IP (+1, +12.5%). Competition is intense (-1, -12.5%). Net adjustment: +25%. Adjusted valuation: ₹10 crore. This is not a formula that produces a 'correct' number — it's a systematic way to justify the premium or discount relative to comparable deals.
Venture Capital Method: What Investors Actually Use
The VC method works backward from the expected exit value and applies the required return to determine today's investment valuation.
Step 1: estimate the company's value at exit in 5–7 years (using sector revenue multiples at expected exit revenue). Step 2: apply the VC's required return rate (typically 10–20x for seed, 5–10x for Series A). Step 3: the result is the post-money valuation the VC is comfortable with.
Example: Expected year-5 revenue ₹50 crore, sector trades at 5x revenue → exit value ₹250 crore. VC needs 15x return on seed investment → seed post-money valuation = ₹250 crore / 15 = ₹16.7 crore. VC invests ₹3 crore → VC owns 3 / 16.7 = 18%. The pre-money valuation is ₹16.7 - ₹3 = ₹13.7 crore.
This is exactly how seed investors think about valuation, which is why founders who understand the VC method can have a more informed negotiation — they can model what the investor is implying about exit expectations and return requirements, and push back on individual assumptions.
Key takeaway
Pre-revenue valuation is a negotiation exercise structured around comparable data and a shared understanding of risk-adjusted potential. Know your comparables, understand the VC return math, and be able to articulate why your specific risks are lower than the average comparable deal.
Frequently asked questions
What is a 'milestone-based valuation' for pre-revenue startups?
A milestone-based valuation breaks the company's development into stages, each with a defined risk-reduction milestone (e.g., 'first ₹10 lakh MRR', 'signed strategic partnership', 'product launched in 3 markets'). Each milestone achieved reduces the risk discount applied to the company's potential value. The current valuation reflects how many milestones have been completed out of the total. This approach is more common in biotech and deep tech where development has clear, binary milestones.
How do accelerators value companies they accept?
Accelerators typically apply standardised terms rather than negotiated valuations. Y Combinator invests $500,000 for 7% (in 2024). 100X.VC in India invests ₹25 lakh for 2%. These standardised terms imply specific post-money valuations, but they're not derived from traditional valuation analysis — they reflect the market-clearing price for accelerator value-add (curriculum, network, brand signal). Getting into a top accelerator adds brand value that often justifies the fixed dilution regardless of what a DCF would say.
Can a startup use its patent applications to increase its valuation?
Patent applications (not yet granted patents) have limited direct valuation impact because the application may be rejected, allowed only in modified form, or granted without scope to protect the core innovation. Granted patents from credible jurisdictions (India, US, EU) have more value, particularly in technology and pharmaceutical companies. The valuation impact of IP depends on whether the IP protects a product/process that generates revenue, whether it creates a genuine competitive barrier, and whether it's been enforced. IP without revenue behind it is narrative, not valuation.
What valuation method does a merchant banker use for a pre-revenue startup under Rule 11UA?
For Rule 11UA compliance, the merchant banker typically uses DCF even for pre-revenue companies, starting projections from ₹0 revenue in year 0 and modelling revenue ramp-up from year 1 or 2. The discount rate is set higher for pre-revenue companies (35–50% for very early stage) to reflect the higher probability that the projected revenues won't materialise. Some merchant bankers also use a probability-weighted scenario analysis for non-resident investments under the expanded Rule 11UA methods introduced in Finance Act 2023.
Is Intellectual Property a meaningful part of startup valuation in India?
For most Indian startups at early stage, no. IP is an upside scenario asset, not a core valuation driver. Exceptions: deep tech companies where the IP is the product (core algorithm, proprietary process), pharmaceutical companies with drug patents, and any company where the IP prevents a large competitor from simply replicating the product. For these, IP-based valuation methods (income approach applied to the IP asset, or cost approach for replacement cost) can form part of the overall business valuation.